Evidence-based therapeutic drug monitoring for ribavirine;Niveau de preuve du suivi therapeutique pharmacologique de la ribavirine

Therapie

Volumn 66, Issue 3, 2011, Pages 221-230

  Solas, Caroline ^a   Paré, Maxime ^a   Quaranta, Sylvie ^a   Stanke Labesque, Françoise ^b,c  

^a TIMONE HOSPITAL   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

^c INSERM   (France)

Author keywords

level of evidence; ribavirin; therapeutic drug monitoring

Indexed keywords

ALPHA INTERFERON; HEMOGLOBIN; RIBAVIRIN; VIRUS RNA;

ANEMIA; ARTICLE; BLOOD TOXICITY; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MONITORING; EVIDENCE BASED MEDICINE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MIXED INFECTION; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT OUTCOME; VIRUS LOAD;

EID: 80051728757     PISSN: 00405957     EISSN: 19585578     Source Type: Journal    
DOI: 10.2515/therapie/2011036     Document Type: Article

References (52)

1. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958-65 (Pubitemid 32913521)
2. Hadziyannis SJ, Sette H. Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140: 346-55
3. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436: 967-72 (Pubitemid 41191673)
4. Feld JJ, Nanda S, Huang Y, et al. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 2007; 46: 1548-63 (Pubitemid 350155537)
5. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123: 1061-9
6. Jen J, Laughlin M, Chung C, et al. Ribavirin dosing in chronic hepatitis C: Application of population pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther 2002; 72: 349-61 (Pubitemid 35178861)
7. Le Guellec C, Simon N, Hulot JS, et al. Evidence-based therapeutic drug monitoring. La lettre du Pharmacologue 2009; 23: 21-5
8. Stanke-Labesque F, Souvignet C, Bronowicki JP, et al. The relationship between serum ribavirin concentration and early virological response is limited to slow viral kinetic responders to combination peg interferon alpha 2a (40 Kd) plus ribavirin therapy in patients with genotype 1-4 HCV. Fundam Clin Pharmacol 2006; 20(2): 105-234
9. Donnerer J, Grahovac M, Stelzl E, et al. Ribavirin levels and haemoglobin decline in early virological responders and non-responders to hepatitis C virus combination therapy. Pharmacology 2006; 76: 136-40 (Pubitemid 43289466)
10. Loustaud-Ratti V, Alain S, Rousseau A, et al. Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology 2008; 47: 1453-61 (Pubitemid 351702729)
11. Rendon AL, Nunez M, Romero M, et al. Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2005; 39: 401-5 (Pubitemid 41003783)
12. Jen JF, Glue P, Gupta S, et al. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 2000; 22: 555-65
13. Larrat S, Stanke-Labesque F, Plages A, et al. Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob Agents Chemother 2003; 47: 124-9 (Pubitemid 36070352)
14. Tsubota A, Hirose Y, Izumi N, et al. Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection. Br J Clin Pharmacol 2003; 55: 360-7 (Pubitemid 36535366)
15. Maynard M, Pradat P, Gagnieu MC, et al. Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients. Antivir Ther 2008;13: 607-11 (Pubitemid 352016724)
16. Arase Y, Ikeda K, Tsubota A, et al. Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C. Intervirology 2005; 48: 138-44 (Pubitemid 41201504)
17. Lindahl K, Stahle L, Bruchfeld A, et al. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005; 41: 275-9 (Pubitemid 40165370)
18. Christensen PB, Alsio AA, Buhl MR, et al. Ribavirin concentration at week four is an independent predictor for sustained viral response after treatment of hepatitis C genotype 2/3 (Nordynamic Trial). 43th EASL Conference, Milan, Italy, April 2008; Abstract 10
19. Nicot F, Legrand-Abravanel F, Lafont T, et al. Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV. J Med Virol 2008; 80: 1523-9
20. Aguilar Marucco D, Gonzalez de Requena D, Bonora S, et al. The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon. J Antimicrob Chemother 2008; 61(4): 919-24 (Pubitemid 351426079)
21. Dahari H, Markatou M, Zeremski M, et al. Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. J Hepatol 2007; 47: 23-30 (Pubitemid 46817685)
22. Morello J, Soriano V, Barreiro P, et al. Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV coinfected patients treated for chronic hepatitis C. Antimicrob Agents Chemother 2010; 54(4): 1647-9
23. Tanaka H, Miyano M, Ueda H, et al. Changes in serum and red blood cell membrane lipids in patients treated with interferon ribavirin for chronic hepatitis C. Clin Exp Med 2005; 5: 190-5 (Pubitemid 41813763)
24. Sulkowski M,Wasserman R, Brooks L, et al. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat 2004; 11: 243-50 (Pubitemid 38658449)
25. Homma M, Matsuzaki Y, Inoue Y, et al. Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia. Clin Gastroenterol Hepatol 2004; 2: 337-9 (Pubitemid 38447199)
26. Lindhal K, Schvarcz R, Bruchfeld A, et al. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J Viral Hepat 2004; 11(1): 84-7 (Pubitemid 38221622)
27. Uchida M, Hamada A, Yamasaki M, et al. Assessment of adverse reactions and pharmacokinetics of ribavirin in combination with interferon alpha-2b in patients with chronic hepatitis C. Drug Metab Pharmacokinet 2004; 19(6): 438-43
28. Inoue Y, Homma M, Matzuzaki Y, et al. Erythrocyte ribavirin concentration for assessing haemoglobin reduction in interferon and ribavirin combination therapy. Hepatol Res 2006; 34: 23-7 (Pubitemid 43091872)
29. Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis 1999; 19(Suppl. 1): 17-24 (Pubitemid 29220816)
30. Wade JR, Snoeck E, Duff F, et al. Pharmacokinetics of ribavirin in patients with hepatitis C virus. Br J Clin Pharmacol 2006; 62: 710-4 (Pubitemid 44749548)
31. Patterson JL, Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. Rev Infect Dis 1990; 12: 1139-46
32. Bruchfeld A, Lindahl K, Schvarcz R, et al. Dosage of ribavirin in patients with hepatitis C should be based on renal function: A population pharmacokinetic analysis. Ther Drug Monit 2002; 24: 701-8 (Pubitemid 35379522)
33. Toyoda H, Kumada T, Kiriyama S, et al. Correlation of serum ribavirin concentration with pretreatment renal function estimates in patients with chronic hepatitis C receiving combination antiviral therapy with peginterferon and ribavirin. J Virol Hepat 2008; 15: 651-8
34. Van Leusen R, Adang RP, de Vries RA, et al. Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2008; 23: 721-5 (Pubitemid 351767641)
35. Rendina M, Schena A, Castellaneta NM, et al. The treatment of chronic hepatitis C with peginterferon alfa-2 (40kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol 2007; 46: 768-74 (Pubitemid 46529043)
36. Glue P, Schenker S, Gupta S, et al. The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease. Br J Clin Pharmacol 2000; 49: 417-21 (Pubitemid 30229444)
37. Dumortier J, Ducos E, Scoazec JY, et al. Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon alpha-2b and ribavirin combination after liver transplantation. J Viral Hepat 2006; 13: 538-43 (Pubitemid 44100405)
38. Fellay J, Thompson AJ, Ge D, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010; 464(7287): 405-8
39. Thompson AJ, Fellay J, Patel K, et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology 2010; 139(4): 1181-9
40. Ochi H, Maekawa T, Abe H, et al. ITPA polymorphism affects ribavirininduced anemia and outcomes of therapy-a genome-wide study of Japanese HCV virus patients. Gastroenterology 2010; 139(4): 1190-7
41. Sakamoto N, Tanaka Y, Nakagawa M, et al. ITPA gene variant protects against anemia induced by pegylated interferon-a and ribavirin therapy for Japanese patients with chronic hepatitis C. Hepatol Res 2010; 40(11): 1063-71
42. Bosch ME, Sanchez AJ, Rojas FS, et al. Ribavirin: Analytical determinations since the origin until today. J Pharm Biomed Anal 2007; 45: 185-93 (Pubitemid 47513418)
43. Austin RK, Trefts PE, Hintz M, et al. Sensitive radioimmunoassay for the broad-spectrum antiviral agent ribavirin. Antimicrob. Agents Chemother 1983; 24: 696-701 (Pubitemid 14203868)
44. Homma M, Jayewardene AL, Gambertoglio J, et al. High-performance liquid chromatographic determination of ribavirin in whole blood to assess disposition in erythrocytes. Antimicrob. Agents Chemother 1999; 43: 2716-9 (Pubitemid 29519553)
45. Morello J, Rodriguez-Novoa S, Cantillano AL, et al. Measurement of ribavirin plasma concentrations by high-performance liquid chromatography using a novel solid-phase extraction method in patients treated for chronic hepatitis C. Ther Drug Monit 2007; 29: 802-6 (Pubitemid 350190858)
46. D'Avolio A, Ibanez A, Sciandra M, et al. Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 835: 127-30
47. L Liu Y, Xu C, Yan R, et al. Sensitive and specific LC-MS/MS method for the simultaneous measurements of viramidine and ribavirin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 832: 17-23 (Pubitemid 43213004)
48. Jourdil JF, Stanke-Labesque F. A sensitive and specific method for the quantification of ribavirin in humanplasma by high performance chromatography-tandem mass spectrometry. Fundam Clin Pharmacol 2008; 22 (Suppl. 1): 84
49. Sauvage FL, Stanke-Labesque F, Gagnieu MC, et al. Feasibility of ribavirin therapeutic drug monitoring in hepatitis C. Ther Drug Monit 2009; 31: 374-81
50. Crespo M, Pou L, Esteban JI, et al. Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIVcoinfected patients. Antivir Ther 2007; 12: 1217-23
51. Inoue Y, Homma M, Matsuzaki Y, et al. Liquid chromatography assay for routine monitoring of cellular ribavirin levels in blood. Antimicrob Agents Chemother 2004; 48: 3813-6 (Pubitemid 39304608)
52. Marquet P, Sauvage FL, Loustaud-Ratti V, et al. Stability of ribavirin concentrations depending on the type of blood collection tube and preanalytical conditions. Ther Drug Monit 2010; 32(2): 237-41